The Expression Of TBX2, PAX9in Epithelial Ovarian Cancer And Its Clinical Significance

Objective: Epithelial ovarian cancer has the highest mortality in thefemale reproductive tract malignant tumor, The early symptoms of ovariancancer patients lack, the vast majority of rapid progress, are diagnosed atadvanced stages, Many patients in the operation plus chemotherapy is stilllikely to disease progression or recurrence appeared in a short time, Therefore,to further clarify the mechanism of epithelial ovarian cancer occurrence anddevelopment, for the early and effective tumor markers and screening of greatsignificance. TBX2belongs to the developmental regulation of transcriptionfactor gene, is one of the members of T-BOX gene family; PAX9is a newmember of the PAX family, is essential for regulation of gene expressionduring embryogenesis. In recent years, the study found the upregulation of theexpression of TBX2, PAX9in a variety of tumors, Can be regarded as a newtumor marker. But the expression of TBX2and PAX9in ovarian epithelialcarcinoma and its clinical significance, there is no relevant research reports.The experimental study on the expression of TBX2, PAX9in normal ovariantissue and ovarian epithelial carcinoma and its clinical significance. Provideguidance and target for the clinical diagnosis and treatment and prognosis ofepithelial ovarian cancer.Methods:1We selected45cases of epithelial ovarian cancer patients’ paraffin andmedical information as study group, all of whom were inpatient in the fourthaffiliated hospital of Hebei medical university from January2008toDecember2009. Among all the patients selected, their ages ranged from40to70years old, with a median age of52years. In the study group, there are15cases of ovarian serous carcinoma,15cases of mucinous carcinoma, and15cases of endometrial carcinoma patients; according to FIGO stage, there are5 cases of stageⅠ,9cases of stage Ⅱ,24cases of stage Ⅲ and7cases ofstage Ⅳ, of which stageⅠ/Ⅱbelongs to early stage(totally14cases), stageⅢ/Ⅳ belongs to late stage(totally31cases);5cases of high-differentiatedcarcinoma,10cases of middle-differentiated carcinoma, and30cases oflow-differentiated;10cases with lymph node metastasis,35cases with nolymph node metastasis;22cases recurred in1year after operation,36casesrecurred in3years, and there are9cases without recurrence. We selectedparaffin and medical information of normal ovarian tissue in the same periodas the control group.2Methods the expression by immunohistochemical detection of TBX2,PAX9in normal ovarian tissue and ovarian epithelial carcinoma.3All the data was analyzed by SPSS13.0software wrap, Count datausing Fisher’s exact probability，Grade data using rank sum test，Thecorrelation between two variables by χ2test analysis，The results of eachgroup with α=0.05as the test standard, with P <0.05had significantdifferenc.Results:1The positive expression rate of TBX2protein in epithelial ovarian carcinomawas77.78%,The positive expression rate in normal ovarian tissues was10%,Comparison between two groups was statistically significant (P＜0.05).2Relationship between the expression of TBX2protein in epithelial ovariancarcinoma and the clinical pathological characteristics.2.1TBX2protein in different pathological type (serous, mucinous,endometrioid) high expression in ovarian carcinoma are presented, Thepositive expression rate were80%,86.67%,66.67%, The positive expressionrate was no significant difference between the three (P>0.05).2.2TBX2protein in early (stage I-II) the positive expression rate was50%inpatients with epithelial ovarian cancer, Advanced (stage III-IV) the positiveexpression rate of90.32%patients, There is significant difference (P <0.05).2.3TBX2protein in high differentiation of ovarian cancer tissues. Thepositive rate was40%, The positive expression rate of60%moderately differentiated carcinoma, Poorly differentiated carcinoma and the positive ratewas90%, There was significant difference between the three (P <0.05).2.4TBX2protein in lymph node metastasis in tissue of patients with positiveexpression rate was90%, The positive expression rate was74.29%in patientswithout lymph node metastasis tissues, No statistical difference (P>0.05).2.5The expression of TBX2protein in35cases of patients,21cases recurredwithin1year, The recurrence rate was60%,31cases of3years the cumulativerecurrence, the recurrence rate was88.57%; the protein expression in theTBX2negative patients,1cases recurred within1year, the recurrence ratewas10%,5cases recurred within3year, the recurrence rate was50%. The1year recurrence rate of expression of TBX2positive and negative, statisticallysignificant difference between two groups (P <0.05);3years recurrence ratebetween positive expression of TBX2protein and the negative, the differencewas statistically significant (P <0.05).3The positive expression rate of PAX9protein in epithelial ovarian carcinomawas88.89%,The positive expression rate in normal ovarian tissues was10%,Comparison between two groups was statistically significant (P＜0.05).4Relationship between the expression of PAX9protein in epithelial ovariancarcinoma and the clinical pathological characteristics.4.1PAX9protein in different pathological type (serous, mucinous,endometrioid) high expression in ovarian carcinoma are presented, thepositive expression rates were93.33%,86.67%,86.67%, rate of positiveexpression was no significant difference between the three (P>0.05).4.2PAX9protein in early (stage I-II) in patients with epithelial ovariancarcinoma the positive rate was71.43%, with advanced (stage III-IV) patients,the positive rate was96.77%, there were significant difference between them(P <0.05).4.3PAX9protein in well differentiated epithelial ovarian carcinoma thepositive rate was60%, the differentiation of the cancer, the positive rate was80%, the low differentiation cancer tissues and the positive rate was96.67%,there was significant difference between the three (P <0.05). 4.4PAX9protein in lymph node metastasis in tissue of patients with positiveexpression rate was100%in patients without lymph node metastasis, theexpression positive rate was85.71%, no statistical difference (P>0.05).4.5The expression of PAX9protein in40cases of patients,22cases recurredwithin1year, the recurrence rate was52%,34cases of3years the cumulativerecurrence, the recurrence rate was85%; the protein expression in the PAX9negative patients,0cases recurred within1year, the recurrence rate was0%,2cases of recurrence within3years, the recurrence rate of40%. The1yearrecurrence rate of expression of PAX9positive and negative, statisticallysignificant difference between two groups (P <0.05);3years recurrence ratebetween positive expression of PAX9protein and the negative, the differencewas statistically significant (P <0.05).5The positive expression of TBX2in epithelial ovarian carcinoma was77.78%, the positive expression of PAX9in epithelial ovarian carcinoma was88.89%, the correlation coefficient of the positive expression rate (r=0.491),was statistically significant (P <0.05).Conclusion:1TBX2and PAX9expression in epithelial ovarian carcinoma wassignificantly higher than the expression in normal ovarian tissues; can be usedas a new marker for epithelial ovarian cancer diagnosis.2TBX2and PAX9closely related proteins in epithelial ovarian cancerexpression and clinical stage, degree of differentiation, recurrence, suggestingthat over expression of TBX2and PAX9promotes ovarian epithelial cellproliferation and transformation to malignant phenotype, reflects the progressand the judgment of the prognosis of ovarian carcinoma with index.3Positive positive expression of TBX2, PAX9in ovarian epithelialcarcinoma related, plays an important role in the development of epithelialovarian cancer, and provides a new idea for the diagnosis and prognosis of epithelial ovarian cancer.